Evidence map›Paper›PMID 41384441›Full record

ArticlemAbs2026

Rapid expression of therapeutic antibodies in mammalian cells via mRNA transfection.

Thornwit Chavalparit, Craig Barry, Helen Gunter, Marianne Gillard, Timothy Mercer, Esteban Marcellin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Thornwit ChavalparitAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia.
Craig BarryAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia.
Helen GunterAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia.
Marianne GillardAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia.
Timothy MercerAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia.
Esteban MarcellinAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Messenger RNA (mRNA) has emerged as a powerful tool for protein expression in clinical settings, yet its potential as a platform for biologics manufacturing remains underexplored. Here, we evaluate transient mRNA transfection in Chinese hamster ovary (CHO) cells as a rapid and versatile system for protein production. Using reporter mRNAs, we optimize transfection efficiency and benchmark performance against industry-standard plasmid transfection and stable cell line methods. We demonstrate that co-transfection of heavy and light chain mRNAs enables the efficient synthesis, assembly and secretion of the monoclonal antibody bevacizumab with high fidelity. Compared to conventional approaches, mRNA transfection drives rapid and predictable protein expression, reducing cell incubation times and enabling sequential or conditional expression. These features highlight mRNA as a flexible and efficient platform for transient expression, providing a foundation for accelerating the development and manufacturing of biologics.

Indexed as

BevacizumabRNA, MessengerTransfectionAnimalsCHO CellsCricetulusHumansBevacizumabRNA, MessengerBevacizumabbiologics manufacturingChinese hamster ovary (CHO) cellsmonoclonal antibodymRNA transient transfection

Identifiers

PMID41384441
PMCPMC12710884

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.